{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:46:25Z","timestamp":1787010385621,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Thrombotic microangiopathy (TMA) following lung transplantation (LTx) is a rare but severe complication. The pathogenesis is poorly understood, and various risk factors have been suggested. In this study, we aimed to evaluate diagnostic accuracy, identify risk factors, and assess renal, pulmonary, and overall survival of TMA in this patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We performed a case-control retrospective study of patients with TMA after LTX between January 1, 2000, and January 1, 2021. Controls were selected based on underlying lung disease, age, sex, cytomegalovirus risk, and immunosuppressive regimen. Overall survival data were collected for the whole lung transplant group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      A total of 29 TMA cases (2.9%) were identified out of 1025 LTx. Median time to development of TMA was 5.9 mo, 76% occurred in the first 12 mo. In the TMA group a higher rate of HLA donor-specific antibodies (11% versus 1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.05), a lower median time to onset of chronic lung allograft dysfunction (37 versus 91 mo;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0017), a higher rate of cytomegalovirus infection (45% versus 19%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02), and a higher prevalence of end-stage renal disease (24% versus 6%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.03) and overall death (97% versus 44%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.0001) was found. Diagnostic assessment of TMA was complete in 48% of patients, with Coombs testing missing in 52% and a disintegrin and metalloproteinase with thrombospondin type 1 motif 13 activity not assessed in 59%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>TMA poses a significant risk of end-stage renal disease and mortality after LTx. Challenges remain in standardizing diagnostic criteria and understanding its pathogenesis, underscoring the need for unified protocols in diagnosis and standardized screening. This study identifies potential risk factors and temporal patterns for TMA occurrence, providing crucial insights for future treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001758","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:00:12Z","timestamp":1741698012000},"page":"e1758","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Thrombotic Microangiopathy: A Devastating Complication After Lung Transplantation"],"prefix":"10.1097","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-1771","authenticated-orcid":false,"given":"Wouter","family":"Rosseels","sequence":"first","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Godinas","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papay","family":"Jallah","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Dupont","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Kuypers","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium."},{"name":"Department of Microbiology, Immunology, and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanhoutte","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium."},{"name":"Department of Microbiology, Immunology, and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Claes","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium."},{"name":"Department of Microbiology, Immunology, and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"R1-20250311","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation.","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transpl Int"},{"key":"R2-20250311","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"R3-20250311","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/CCO.0b013e3280148a2f","article-title":"Thrombotic microangiopathy following allogenic hematopoietic stem cell transplantation.","volume":"19","author":"Kojouri","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"R4-20250311","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.tp.0000188140.50673.63","article-title":"Thrombotic microangiopathy after lung transplantation.","volume":"81","author":"Hachem","year":"2006","journal-title":"Transplantation"},{"key":"R5-20250311","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007890-201211271-00357","article-title":"Thrombotic microangiopathy after lung transplantation: 736.","volume":"94","author":"Scheed","year":"2012","journal-title":"Transplantation"},{"key":"R6-20250311","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/j.1600-6143.2008.02342.x","article-title":"Renal histopathological lesions after lung transplantation in patients with cystic fibrosis.","volume":"8","author":"Lefaucheur","year":"2008","journal-title":"Am J Transplant"},{"key":"R7-20250311","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/j.1600-6143.2010.03224.x","article-title":"Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues.","volume":"10","author":"Schwarz","year":"2010","journal-title":"Am J Transplant"},{"key":"R8-20250311","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2006-939763","article-title":"Thrombotic thrombocytopenic purpura\u2014then and now.","volume":"32","author":"Galbusera","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R9-20250311","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","article-title":"The role of endothelial injury in thrombotic microangiopathy.","volume":"56","author":"Goldberg","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R10-20250311","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ndt\/16.8.1725","article-title":"Thrombotic microangiopathy following renal ischemia and revascularization: apoptosis of endothelial cells in action.","volume":"16","author":"Cailhirt","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R11-20250311","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.trre.2011.05.001","article-title":"Emerging role of innate immunity in organ transplantation: part 1: evolution of innate immunity and oxidative allograft injury.","volume":"26","author":"Land","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"R12-20250311","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non-renal solid organ transplantation.","volume":"28","author":"Verbiest","year":"2014","journal-title":"Blood Rev"},{"key":"R13-20250311","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American Society for Apheresis: the eight special issue.","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"R14-20250311","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2011.339","article-title":"AKI in the ICU: definition, epidemiology, risk stratification, and outcomes.","volume":"81","author":"Singbartl","year":"2012","journal-title":"Kidney Int"},{"key":"R15-20250311","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R16-20250311","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"R17-20250311","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R18-20250311","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int"},{"key":"R19-20250311","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1034\/j.1399-3062.2003.00019.x","article-title":"Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review.","volume":"5","author":"Ramasubbu","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"R20-20250311","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1128\/JVI.79.4.2211-2220.2005","article-title":"Human cytomegalovirus of endothelial cells triggers platelet adhesion and aggregation.","volume":"79","author":"Rahbar","year":"2005","journal-title":"J Virol"},{"key":"R21-20250311","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.healun.2012.11.018","article-title":"Pathologic findings in lung allografts with anti-HLA antibodies.","volume":"32","author":"DeNicola","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R22-20250311","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.ajt.2023.06.003","article-title":"Defining a natural killer cell-enriched molecular rejection-like state in lung transplant transbronchial biopsies.","volume":"23","author":"Gauthier","year":"2023","journal-title":"Am J Transplant"},{"key":"R23-20250311","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fimmu.2017.00166","article-title":"Dual role of natural killer cells on graft rejection and control of cytomegalovirus infection in renal transplantation.","volume":"8","author":"L\u00f3pez-Botet","year":"2017","journal-title":"Front Immunol"},{"key":"R24-20250311","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"R25-20250311","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","article-title":"Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies.","volume":"18","author":"Werion","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-20250311","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40620-021-00981-8","article-title":"Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort.","volume":"35","author":"Aigner","year":"2022","journal-title":"J Nephrol"},{"key":"R27-20250311","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical hemolytic uremic syndrome.","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20250311","doi-asserted-by":"crossref","first-page":"1701248","DOI":"10.1183\/13993003.01248-2017","article-title":"Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.","volume":"50","author":"Verleden","year":"2017","journal-title":"Eur Respir J"},{"key":"R29-20250311","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/j.healun.2022.01.703","article-title":"Survival after lung transplantation in Europe\u2014CLAD as major cause of death.","volume":"41","author":"Hofstetter","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R30-20250311","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/TP.0000000000000549","article-title":"Incidence","volume":"99","author":"Santos","year":"2015","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:00:27Z","timestamp":1741698027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001758","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}